All News
Khanna et al Transdermal NaHCO₃ in gout flare. N=98. Response rate D7 95% vs 79% (p=0.01). Lower rescue med, 6% vs 20%. @RheumNow #ACR22 Abstr#1787 https://t.co/DWtlvjzBHw https://t.co/DOk993gCwz
Richard Conway RichardPAConway ( View Tweet)
Joy et al. Disease activity rather than steroid use increases risk of diabetes in RA in BeST study over 10 years. @RheumNow #ACR22 Abstr#1987 https://t.co/VT2eb3Q4m9 https://t.co/kquZ70o9bU
Richard Conway RichardPAConway ( View Tweet)
L08 #ACR22 TIX/CIL (Evusheld) in Rheum Pts
157 pts, f/u 154 days
24 breakthrough COVID ifns (15%)
2 pts required hospitalization, rest had mild-mod symptoms
No SAEs (CVD)
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
#ACR22 Best in PsA and SpA - new Rxs, unraveling responses to Rx by sex/gender. X-ray inhibition w SpA drugs is a reality. Nice peeps working in these areas @RheumNow @ACRheum https://t.co/8VfdyyHPZi
Janet Pope Janetbirdope ( View Tweet)
Here's the 1 year model #ACR22 @RheumNow https://t.co/VhEuJMMyIt
Richard Conway RichardPAConway ( View Tweet)
Eder et al. New PRESTO prediction model for PsA development in PsO. 1 year and 5 year models presented @RheumNow #ACR22 Abstr#1612 https://t.co/xMMVaIGnN5 https://t.co/RlJ3ZlEeDE
Richard Conway RichardPAConway ( View Tweet)
Krijbolder et al. TREAT EARLIER DBRCT. MTX vs PBO for pre-RA. Treat 1 year, stop, and follow 1 year. No difference in RA development. Delay in ACPA+ or high risk. Sustained benefit in MTX group on pain, EMS, function, MRI. @RheumNow #ACR22 Abstr#1603 https://t.co/M2qQfgrhC1 https://t.co/UUeknTLx0K
Richard Conway RichardPAConway ( View Tweet)
Yazici et al. RCT of IA Lorecivivint for moderate/severe knee OA. CLK/DYRK inhibitor. No effect seen. @RheumNow #ACR22 Abstr#1899 https://t.co/XGQrMmNnSR https://t.co/rSJrT6Hms6
Richard Conway RichardPAConway ( View Tweet)
Bihlet et al. Anti-histamines may reduce structural progression of knee OA. Post-hoc analysis of 2 trials @RheumNow #ACR22 Abstr#1893 https://t.co/RrrelHDz75 https://t.co/Sf7RpjjAaN
Richard Conway RichardPAConway ( View Tweet)
Post-hoc analysis of SELECT-COMPARE showing decreased residual pain at week 12 but not week 26 cf. ADA, regardless of residual inflammation. Does this just reflect differing onset of action?
@RheumNow ABST0297 #ACR22
https://t.co/9WyZAN3B16 https://t.co/fAC1bLw9EB
Julian Segan JulianSegan ( View Tweet)
Shanahan et al. RCT of Genicular nerve block for knee OA. It works but temporary, with loss of effect by week 12. @RheumNow #ACR22 Abstr#1892 https://t.co/VySjBGrVeR https://t.co/JNKQeOVB6z
Richard Conway RichardPAConway ( View Tweet)
In a prospective cohort where MTX was withheld for 1 week post COVID vaccine, antibodies higher than other DMARDs which were continued (mostly RTX/MMF).
Good to see more direct data rather than having to extrapolate from flu.
@RheumNow ABST0913 #ACR22
https://t.co/YphKywNJfA
Julian Segan JulianSegan ( View Tweet)
Please find our Day 2 #ACR22 Daily Recap Video by @RheumNow Faculty
https://t.co/f3BbKkgzRp
@Janetbirdope @synovialjoints @doctorRBC @bella_mehta @AkhilSoodMD @RHEUMarampa @DrCassySims https://t.co/VZM53cUyWL
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Ho et al. Consistent colchicine use assoc reduction in MACE in patients with gout and pre-existing CVD. @RheumNow #ACR22 Abstr#1815 https://t.co/tXwa2FrSrp https://t.co/8TKl4z7iaH
Richard Conway RichardPAConway ( View Tweet)
Kastrati et al. Case series immune apheresis in IIM. 24 patients. Reduced CK in 21/24, 971 to 347. Reduced steroid 25%, median 12.5mg reduction @RheumNow #ACR22 Abstr#1882 https://t.co/UUlm4xEX61 https://t.co/bS2IA9OKnH
Richard Conway RichardPAConway ( View Tweet)
"If your partner won't use protection, close the vault!" - Dr. J Patricia Dhar interviewed on sexual Health and STD Prevention in Lupus Patients. Contact her pdhar@med.wayne.edu if you want to collaborate or fund her studies. #ACR22 @rheumnow https://t.co/WDLq9Mhoiw
TheDaoIndex KDAO2011 ( View Tweet)
Does curcurmin (tumeric) do anything in RA?
Big talk & sales.
Best chance would be keeping pts in remission during csDMARD taper:
DBRCT n=200
52w, high bioavail form, good serum conc
Absolutely nothing vs placebo
I'll call it: just doesn't work in RA
ABST1587 #ACR22 @RheumNow https://t.co/wecEfkXT55
David Liew drdavidliew ( View Tweet)
Flood @FloodRachael et al. ULT reduces non-episodic foot pain in hyperuricaemic patients who fail to meet gout classification criteria. Predicted by double counter or tophus on US. @RheumNow #ACR22 Abstr#1828 https://t.co/iOy0Vo5HVO https://t.co/vF98DFB7hJ
Richard Conway RichardPAConway ( View Tweet)
McCormick et al Fruit juice and other sugar-sweetened drinks increase gout flare in dose-dependent manner @RheumNow #ACR22 Abstr#1805 https://t.co/aGg5i5XyTK https://t.co/x8ChwASM6P
Richard Conway RichardPAConway ( View Tweet)
A Novel Treatment Response Measurement Tool for Lupus
Dr. Dao discusses abstract 2054 with Dr. Morand at the #ACR22 Convergence. Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process.
https://t.co/iqqyI953Vz https://t.co/taUjTHsrJ2
Links:
Dr. John Cush RheumNow ( View Tweet)